Study identifier:D4191R00028
ClinicalTrials.gov identifier:NCT05933044
EudraCT identifier:N/A
CTIS identifier:N/A
A Retrospective Observational, Multi-Centre, Cohort Study to Understand Real-World Treatment Patterns and Clinical Outcomes of Adult Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada
Non-small Cell Lung Cancer
N/A
No
Durvalumab
All
662
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2023 by AstraZeneca
AstraZeneca
-
In the RELEVANCE study, we will develop a scalable electronic medical report data capture platform to collect and analyse real-world data in the stage III NSCLC population in Canada across several Canadian cancer centres. Subsequent analyses will examine treatment patterns and clinical outcomes, including overall survival, for these patients, stratified by durvalumab regimen or non-durvalumab regimen during the time of the PACIFIC Patient Support Program.
Location
Location
Calgary, Alberta, Canada, T2N 1N4
Location
Vancouver, British Columbia, Canada, V5Z 4E6
Location
Halifax, Nova Scotia, Canada, B3H 2Y9
Location
Montreal, Quebec, Canada, H2X 3E4
Location
Ottawa, Ontario, Canada, K1H 8L6
Arms | Assigned Interventions |
---|---|
Durvalumab cohort All stage III non-small cell lung cancer (NSCLC) patients who received durvalumab | Drug: Durvalumab Chemoradiotherapy plus durvalumab Other Name: Imfinzi |
Non-durvalumab cohort All stage III non-small cell lung cancer (NSCLC) patients who did not receive durvalumab | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.